References
- HagymásiKMüllnerKHerszényiLTulassayZUpdate on the pharmacogenomics of proton pump inhibitorsPharmacogenomics201112687388821692617
- GardinerSJBeggEJPharmacogenetics, Drug-Metabolizing Enzymes, and Clinical PracticePharmacol Rev200658352159016968950
- FurutaTShiraiNSugimotoMOhashiKIshizakiTPharmacogenomics of table proton pump inhibitorsPharmacogenomics20045218120215016609
- ChaudhryASKochharRKohliKKGenetic polymorphism of CYP2C19 and therapeutic response to proton pump inhibitorsIndian J Med Res2008127652153018765869
- FurutaTShiraiNTakashimaMEffects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillinPharmacogenetics200111434134811434512
- FurutaTShiraiNTakashimaMEffect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycinClin Pharmacol Ther200169315816811240980
- Gawrońska-SzklarzBSiudaAKurzawskiMBielickiDMarliczWDroździkMEffects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazoleEur J Clin Pharmacol201066768168720376628
- SimSRisingerCDahlMLCommon novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClin Pharmacol Ther200679110311316413245
- YangJCLinCJCYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infectionExpert Opin Drug Metab Toxicol201061294119968574
- BaldwinRMOhlssonSPedersenRSIncreased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteersBr J Clin Pharmacol200865576777418294333
- FurutaTSugimotoMShiraiNIndividualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19Mol Diagn Ther201216422323422873740
- De MoraisSMWilkinsonGRBlaisdellJMeyerUANakamuraKGoldsteinJAIdentification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in JapaneseMol Pharmacol19944645945987969038
- GaikovitchEACascorbiIMrozikiewiczPMPolymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian populationEur J Clin Pharmacol200359430331212879168
- HermanDDolzanVBreskvarKGenetic polymorphism of cytochromes P450 2C9 and 2C19 in Slovenian populationZdrav Vestn200372347351
- ScordoMGCaputiAPD’ArrigoCFavaGSpinaEAllele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian populationPharmacol Res200450219520015177309
- ArvanitidisKRagiaGIordanidouMGenetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek populationFundam Clin Pharmacol200721441942617635181
- BozinaNGranićPLalićZTramisakILovrićMStavljenić-RukavinaAGenetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian populationCroat Med J200344442542812950145
- TammingaWJWemerJOosterhuisBde ZeeuwRAde LeijLFJonkmanJHThe prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteersEur J ClinPharmacol20015710717722
- BrockmöllerJRostKLGrossDSchenkelARootsIPhenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutationPharmacogenetics19955280887663532